[Use of tocilizumab, an antibody against interleukin-6 receptor, for the treatment of neuromyelitis optica].


Our lab has previously shown that Interleukin (IL)-6- dependent production of autoantibodies against aquaporin 4 in plasmablasts may play a central role in the pathogenesis of neuromyelitis optica (NMO). In this study, we explored the efficacy of tocilizumab, a humanized antibody against IL-6 receptor, in intractable cases of NMO. Eight NMO patients who… (More)
DOI: 10.11477/mf.1416200004


  • Presentations referencing similar topics